Issue 7/2025
Dobrev, H., Todorova, L., Aleksiev, T., Ivanova, Z.
Section of Dermatology and Venereology, Department of Propaedeutics of Surgical
Diseases, Faculty of Medicine, Medical University – Plovdiv
Modern treatment of breast cancer involves the use of biological agents. Alpelisib is an oral alpha-selective PI3K inhibitor used in combination with Fulvestrant (an antiestrogen) in the treatment of postmenopausal women and men with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic carcinoma with a PIK3CA mutation. Its use is associated with a high frequency of side effects, the most common of which are hyperglycemia and skin rash. We report a patient who developed drug-induced maculopapular dermatitis 12 days after starting treatment with Alpelisib.
Address for correspondence:
Prof. Dr. H. Dobrev, MD
Section of Dermatology and Venereology,
Department of Propaedeutics of Surgical Diseases,
Faculty of Medicine, Medical University – Plovdiv
15A, Vasil Aprilov, Blvd.
4002, Plovdiv